Drug
5-ASA
5-ASA is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_3
2
67%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (66.7%)
Phase 41 (33.3%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA
NCT05992142
completedphase_3
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).
NCT02665845
completedphase_3
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
NCT01532648
Clinical Trials (3)
Showing 3 of 3 trials
NCT05992142Phase 4
ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA
NCT02665845Phase 3
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).
NCT01532648Phase 3
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3